Neovascularization promoters which contain as the active ingredient compounds represented by general formula (I), wherein R1 represents acyl; R2 represents alkyl; R3 and R4 are the same or different and each represents hydrogen or a hydroxy-protective group; and R5 represents alkyl. These compounds not only have the effect of promoting neovascularization by themselves but also potentiate neovascularization by drugs having neovascularizing effects such as b-FGF. Therefore, there compounds can potentiate the neovascularization in an ischemic tissue or at a site where b-FGF is locally increased due to other pathological factors.